Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
HOTH has entered a partnership agreement with Zylö Therapeutics Inc to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Therapeutic options for CLE are limited to steroids (topical and oral), topical calcineurin inhibitors, and other immunomodulating therapies that could have adverse effects during long-term use.
HT-005 Z-Pods™ includes a novel topical delivery matrix (Z-Pods™) loaded with an endogenous ligand with suspected immune-modulating action. Z-Pods™ use patented xerogel-derived nanoparticles for sustained and controlled topical delivery of active pharmaceutical ingredients.
For more information on the Z-Pod™ technology, please visit http://www.zylotherapeutics.com/.
The HT-005 Z-Pods™ product is currently in the late preclinical stage of development.